Mirko Buchholz

Dr. Mirko Buchholz

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2005 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MBMirko Buchholz
Mirko Buchholz
UHUlrich Heiser
Ulrich Heiser
SSStephan Schilling
Stephan Schilling
ANAndré J. Niestroj
André J. Niestroj
KZKatrin Zunkel
Katrin Zunkel
HDHans-Ulrich Demuth
Hans-Ulrich Demuth

15 July 2008 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
SSStephan Schilling
Stephan Schilling
TAThomas Appl
Thomas Appl
THTorsten Hoffmann
Torsten Hoffmann
HCHolger Cynis
Holger Cynis
KSKatrin Schulz
Katrin Schulz
HDHans‐Ulrich Demuth
Hans‐Ulrich Demuth
Modified amyloid β (Aβ) peptides represent major constituents of the amyloid deposits in Alzheimer’s disease and Down’s syndrome. In particular, N‐terminal pyroglutamate (pGlu) following truncation renders Aβ more stable, increases hydrophobicity and the aggregation velocity. Recent evidence based on in vitro studies suggests that the cyclization of glutamic acid, leading to pGlu‐Aβ, is catalyzed by the enzyme glutaminyl cyclase (QC) following limited proteolysis of Aβ at the N‐terminus. Here, we studied the pGlu‐formation by rat QC in vitro as well as after microinjection of Aβ(1–40) and Aβ(3–40) into the rat cortex in vivo/in situ with and without pharmacological QC inhibition. Significant pGlu‐Aβ formation was observed following injection of Aβ(3–40) after 24 h, indicating a catalyzed process. The generation of pGlu‐Aβ from Aβ(3–40) was significantly inhibited by intracortical microinjection of a QC inhibitor. The study provides first evidence that generation of pGlu‐Aβ is a QC‐catalyzed process in vivo. The approach per se offers a strategy for a rapid evaluation of compounds targeting a reduction of pGlu formation at the N‐terminus of amyloid peptides.

19 August 2013 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DRDaniel Ramsbeck
Daniel Ramsbeck
MBMirko Buchholz
Mirko Buchholz
BKBirgit Koch
Birgit Koch
LBLivia Böhme
Livia Böhme
THTorsten Hoffmann
Torsten Hoffmann
UHUlrich Heiser
Ulrich Heiser

28 October 2009 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MBMirko Buchholz
Mirko Buchholz
AHAntje Hamann
Antje Hamann
SASusanne Aust
Susanne Aust
WBWolfgang Brandt
Wolfgang Brandt
LBLivia Böhme
Livia Böhme
UHUlrich Heiser
Ulrich Heiser

2 November 2016 in Marine Drugs
Verified
Journal Article
Open access
PDF file
SHStephanie Hielscher-Michael
Stephanie Hielscher-Michael
CGCarola Griehl
Carola Griehl
MBMirko Buchholz
Mirko Buchholz
HDHans-Ulrich Demuth
Hans-Ulrich Demuth
NANorbert Arnold
Norbert Arnold
LWLudger A. Wessjohann
Ludger A. Wessjohann
In recent years, many new enzymes, like glutaminyl cyclase (QC), could be associated with pathophysiological processes and represent targets for many diseases, so that enzyme-inhibiting properties of natural substances are becoming increasingly important. In different studies, the pathophysiology connection of QC to various diseases including Alzheimer’s disease (AD) was described. Algae are known for the ability to synthesize complex and highly-diverse compounds with specific enzyme inhibition properties. Therefore, we screened different algae species for the presence of QC inhibiting metabolites using a new “Reverse Metabolomics” technique including an Activity-correlation Analysis (AcorA), which is based on the correlation of bioactivities to mass spectral data with the aid of mathematic informatics deconvolution. Thus, three QC inhibiting compounds from microalgae belonging to the family of sulfolipids were identified. The compounds showed a QC inhibition of 81% and 76% at concentrations of 0.25 mg/mL and 0.025 mg/mL, respectively. Thus, for the first time, sulfolipids are identified as QC inhibiting compounds and possess substructures with the required pharmacophore qualities. They represent a new lead structure for QC inhibitors.

Verified
Journal Article
Open access
PDF file
ASAnett Stephan
Anett Stephan
SHSimone Hahn-Löbmann
Simone Hahn-Löbmann
FRFred Rosche
Fred Rosche
MBMirko Buchholz
Mirko Buchholz
AGAnatoli Giritch
Anatoli Giritch
YGYuri Gleba
Yuri Gleba
Colicins are natural non-antibiotic bacterial proteins with a narrow spectrum but an extremely high antibacterial activity. These proteins are promising food additives for the control of major pathogenic Shiga toxin-producing E. coli serovars in meats and produce. In the USA, colicins produced in edible plants such as spinach and leafy beets have already been accepted by the U. S. Food and Drug Administration (FDA) and U. S. Department of Agriculture (USDA) as food-processing antibacterials through the GRAS (generally recognized as safe) regulatory review process. Nicotiana benthamiana, a wild relative of tobacco, N. tabacum, has become the preferred production host plant for manufacturing recombinant proteins—including biopharmaceuticals, vaccines, and biomaterials—but the purification procedures that have been employed thus far are highly complex and costly. We describe a simple and inexpensive purification method based on specific acidic extraction followed by one chromatography step. The method provides for a high recovery yield of purified colicins, as well as a drastic reduction of nicotine to levels that could enable the final products to be used on food. The described purification method allows production of the colicin products at a commercially viable cost of goods and might be broadly applicable to other cost-sensitive proteins.